$IBIO I believe you can still be long and bullish and still vote, “No” with respect to all (or some) of the issues on tap for next month. The preservation of shareholder confidence is paramount with any reputable and sustainable company—as is, transparency. This is not a novel concept. For me, I’m not comfortable with Tom moving the goalpost with respect to toxicology reports without any reassurance to investors or communication as to why. I don’t underestimate the task at hand, but leaving us in the dark doesn’t exactly boost shareholder confidence and morale—even for Longs. Yes, long-term (2-3 years), iBio is a solid play, but just because I’m “Long” and “Bullish” does not mean that I should vote yes to dilute my position without a better explanation than was articulated this afternoon.